177Lu-PSMA radioligand therapy is a promising new option for patients with metastasized castration-resistant prostate cancer, and the spectrum of adverse events with this treatment has to be evaluated. Here, we describe the case of a patient with M1c disease (metastasis to the mediastinum, lungs, bones, and liver) who presented with elevated liver enzyme levels after receiving 177Lu-PSMA radioligand therapy for castration-resistant prostate cancer. Pretreatment 68Ga-PSMA PET/CT showed at least 4 liver lesions with low uptake. Overall, the liver uptake was inhomogeneous. Liver biopsy was performed subsequently.
Keywords: 177Lu-PSMA RLT; PSMA radioligand therapy; genitourinary oncology; mCRPC; prostate cancer; radionuclide therapy.
COPYRIGHT © 2021 by the Society of Nuclear Medicine and Molecular Imaging.